<DOC>
	<DOCNO>NCT02000947</DOCNO>
	<brief_summary>The purpose study determine MEDI4736 adequately tolerate combination tremelimumab subject advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Phase 1b Study MEDI4736 Combination With Tremelimumab Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This multicenter , open-label , dose-escalation , dose expansion study MEDI4736 combination tremelimumab evaluate safety , tolerability , pharmacokinetic ( PK ) , immunogenicity , antitumor activity MEDI4736 combination tremelimumab adult subject advance NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Age â‰¥ 18 year 2 . Advanced nonsmall cell lung cancer 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 4 . Adequate organ marrow function 1 . Any concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment 2 . Current prior use immunosuppressive medication within 14 day first dose study drug 3 . Active prior document autoimmune disease within last 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>anti-CTLA-4</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IMTC</keyword>
</DOC>